

# PEER-REVIEWED ORIGINAL RESEARCH PUBLICATIONS

## David Halpin

### PUBLICATIONS:

#### Books:

1. **Halpin DMG**. *COPD*. London: Mosby; 2001. – Also published in Dutch, Swedish, Canadian, Greek, Spanish & Italian editions
2. **Halpin DMG**, et al. *Current COPD*, 1st ed. London: Science Press; 2002.
3. **Halpin DMG**. *Your Questions Answered: COPD*. London: Elsevier; 2003. – Also published in a Greek edition
4. **Halpin DMG**, et al. *Current COPD*, 2nd ed. London: Science Press; 2006.
5. National Institute for Clinical Excellence (NICE). *Anaemia management in Chronic Kidney Disease. National clinical guideline for management in adults and children*. London: Royal College of Physicians; 2006. [Full Text]
6. National Institute for Clinical Excellence (NICE). *Chronic Kidney Disease. National clinical guideline for management in adults in primary and secondary care*. London: Royal College of Physicians; 2008. [Full Text]

#### Chapters in Books:

1. Cooper C, **Halpin D**, et al. Chronic Obstructive Pulmonary Disease. Leach R, Bell D, Moore K (eds). *Oxford Desk Reference Acute Medicine*. Oxford: Oxford University Press; 2016. [Full Text]
2. **Halpin DMG**. COPD. Black R, Hughes M (eds). *Advanced Respiratory Critical Care. Oxford Specialist Handbook Series*. Oxford: Oxford University Press; 2011. [Full Text]
3. **Halpin DMG**, et al. Pneumonia. Black R, Hughes M (eds). *Advanced Respiratory Critical Care. Oxford Specialist Handbook Series*. Oxford: Oxford University Press; 2011. [Full Text]
4. **Halpin DMG**. COPD pathophysiology. Maskell N, Millar A (eds). *Oxford Desk Reference Respiratory Medicine*. Oxford: Oxford University Press; 2009.
5. **Halpin DMG**. Chronic Obstructive Pulmonary Disease. Dilworth JP, Baldwin D (eds). *Handbook of Respiratory Medicine*. Reading: Harwood Academic; 2001.
6. **Halpin DMG**, et al. Bronchoscopy. Brewis RAL, Gibson GJ, Geddes DM (eds). *Respiratory Medicine*, 2nd ed. London: Ballière Tindall; 1995. [Full Text]
7. **Halpin DMG**, et al. Rheumatoid arthritis and connective tissue associated obliterative bronchiolitis. Epler GR (eds) *Diseases of the bronchioles*. New York: Raven Press; 1994. [Full Text]
8. **Halpin DMG**. Blood glucose homeostasis. Hobsley M, Imms FJ (eds). *Physiology in surgical practice*. London: Edward Arnold; 1992.
9. **Halpin DMG**. Tests of endocrine function. Hobsley M, Imms FJ (eds). *Physiology in surgical practice*. London: Edward Arnold; 1992.
10. **Halpin DMG**. Growth and development. Hobsley M, Imms FJ (eds). *Physiology in surgical practice*. London: Edward Arnold; 1992.
11. **Halpin DMG**. Puberty, the menstrual cycle and the menopause. Hobsley M, Imms FJ (eds). *Physiology in surgical practice*. London: Edward Arnold; 1992.

#### Papers:

1. Charlton HM, **Halpin DMG**, et al. Distribution of 125I-labelled follicle-stimulating hormone and human chorionic gonadotrophin in the gonads of hypogonadal (*hpg*) mice. *J Endocrinol* 1982; 93(2): 247-252. [PubMed] [Full Text]
2. Charlton HM, **Halpin DMG**, et al. The effects of daily administration of single and multiple injections of gonadotrophin-releasing hormone on pituitary and gonadal function in the hypogonadal (*hpg*) mouse. *Endocrinology* 1983; 113(2): 535-544. [PubMed] [Full Text]
3. Charlton HM, **Halpin DMG**, et al. Prolactin measurements in normal and hypogonadal (*hpg*) mice: developmental and experimental studies. *Endocrinology* 1983; 113(2): 545-548. [PubMed] [Full Text]
4. Hume DA, **Halpin DMG**, et al. The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: macrophages of endocrine organs. *Proc Natl Acad Sci USA* 1984; 81(13): 4174-4177. [PubMed] [Full Text]
5. Price J, **Halpin DMG**, et al. Plasma corticotrophin-releasing factor-like immunoreactivity in pregnancy. *Arch Gynecol* 1985; 237(suppl):117. **Halpin DMG**, et al. Postnatal ovarian follicle development in hypogonadal (*hpg*) and normal mice and associated changes in the hypothalamic-pituitary ovarian axis. *J Reprod Fertil* 1986; 77(1): 287-296. [PubMed] [Full Text]
6. **Halpin DMG**, et al. Effects of gonadotrophin deficiency on follicle development in hypogonadal (*hpg*) mice. *J Reprod Fertil* 1986; 78(1): 119-125. [PubMed] [Full Text]
7. **Halpin DMG**. Melasma suprarenale: Thomas Addison and the endocrine renaissance. *St Thomas's Hospital Gazette* 1986; 83: 21-24.
8. Higgins JRA, **Halpin DMG**, et al. Penetrating injury on an artificial ski slope. *Injury* 1987; 18(5): 342-343. [PubMed] [Full Text]

9. **Halpin DMG**, et al. The effects of short term injection of gonadotrophins on ovarian follicle development in hypogonadal (*hpg*) mice. *J Reprod Fertil* 1988; 82(1): 393-400. [PubMed] [Full Text]
10. Higgins JRA, **Halpin DMG**, et al. Tension pneumoperitoneum: a surgical emergency. *Br J Hosp Med* 1988; 39(2): 160-161. [PubMed]
11. **Halpin DMG**, et al. VP-1 antigen in chronic postviral fatigue syndrome. *Lancet* 1989; 1(8645): 1028-1029. [PubMed] [Full Text]
12. **Halpin DMG**, et al. Type 1 Arnold-Chiari malformation in a 77 year old woman. *J Neurol Neurosurg Psychiatr* 1990; 53(1): 88-89. [PubMed] [Full Text]
13. **Halpin DMG**, et al. Serum testosterone levels in women with Cushing's disease. *Acta Endocrinol* 1990; 122(1): 71-75. [PubMed] [Full Text]
14. Sorrel M, **Halpin DMG**. Art and neurology. A discussion. *Br J Aesthetics* 1991; 31(3): 241-250. [Full Text]
15. **Halpin DMG**, et al. Sex of children born to women with cystic fibrosis. *Lancet* 1992; 339(8799): 990. [PubMed] [Full Text]
16. **Halpin DMG**, et al. Coffee worker's asthma in a high street coffee shop. *Short Cases in Respiratory Medicine* Volume 2 1994.
17. **Halpin DMG**, et al. Extrinsic allergic alveolitis in a sawmill worker. Case report and review of the literature. *Occup Environ Med* 1994; 51(3): 160-164. [PubMed] [Full Text]
18. **Halpin DMG**, et al. Respiratory symptoms, immunological responses and aeroallergen levels at a sawmill. *Occup Environ Med* 1994; 51(3): 165-172. [PubMed] [Full Text]
19. Bramwell E, **Halpin DMG**, et al. Home intravenous antibiotics in patients with cystic fibrosis using the Intermate infusion device: the first year's experience. *J Advanced Nursing* 1995; 22(6): 1063-1067. [PubMed] [Full Text]
20. Forsling ML, **Halpin D**, et al. Daily patterns of neurohypophysial hormones in man: effect of age. *Exp Physiol* 1998; 83(3): 409-18. [PubMed] [Full Text]
21. Connolly KC, **Halpin DMG**, et al. Challenging current asthma treatment guidelines: improved control of asthma symptoms with nebulised budesonide in patients with severe asthma receiving continuous oral steroids. *Dis Manage Health Outcomes* 2000; 7(4): 217-225. [Full Text]
22. Clarke CE, **Halpin DMG**, et al. Asthma following childhood pneumonia. *BMJ* 2000; 320(7248):1514-16. [PubMed] [Full Text]
23. Sweeny KG, **Halpin DMG**, et al. A comparison of professionals' and patients understanding of asthma: evidence of emerging dualities? *Med Humanit* 2001; 27(1): 20-25. [PubMed] [Full Text]
24. **Halpin DMG**. Managing pneumonia in general practice. *Practitioner* 2001; 245(1619):108-115. [PubMed]
25. **Halpin DMG**. Managing chronic obstructive pulmonary disease. *Drug and Therapeutics Bulletin* 2001; 39: 81-85. [Full Text]
26. Seamark DA, **Halpin DMG**, et al. Home or surgery based screening for chronic obstructive pulmonary disease (COPD)? *Prim Care Respir J* 2001; 10(2): 30-33. [Full Text]
27. **Halpin DMG**. Diagnostics: Spirometry in general practice – where are we now? *Respiratory Disease in Practice*. 2001; 18: 8-11.
28. Greaves C, **Halpin D**, et al. Attack context: an important mediator of the relationship between psychological status and asthma outcomes. *Thorax* 2002; 57(3): 217-221. [PubMed] [Full Text]
29. Ward JA, **Halpin DMG**, et al. Feasibility and effectiveness of a pulmonary rehabilitation programme in a community hospital setting. *Br J Gen Pract* 2002 ;52(480): 539-542. [PubMed] [Full Text]
30. **Halpin DMG**. Editorial. *Drugs in Context* 2003; Issue 003.
31. Celli B, **Halpin D**, et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). *Respir Med* 2003; 97(Suppl A): S35-43. [PubMed] [Full Text]
32. **Halpin DMG**. NICE guidance for COPD. *Thorax* 2004; 59(3): 181-182. [PubMed] [Full Text]
33. **Halpin DMG**. Bronchodilators in COPD: the long and the short of it. *The Airways Journal* 2004; 2:30-32.
34. Seamark DA, **Halpin DMG**, et al. Living with severe chronic obstructive pulmonary disease (COPD): perceptions of patients and their carers. *Palliat Med* 2004; 18(7): 619-625. [PubMed] [Full Text]
35. Ward DG, **Halpin DMG**, et al. How accurate is a diagnosis of asthma in a general practice database? A review of patients' notes and questionnaire reported symptoms. *Br J Gen Pract* 2004; 54(507): 753-758. [PubMed] [Full Text]
36. Greaves CJ, **Halpin DMG**, et al. Patterns of corticosteroid medication use: non-adherence can be effective in milder asthma. *Prim Care Respir J* 2005; 14(2): 99-105. [PubMed] [Full Text]
37. **Halpin DMG**. NICE versus nGMS: what the evidence tells us. *Prim Care Respir J* 2005; 14(1): 8-10. [PubMed] [Full Text]
38. **Halpin DMG**. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. *Int J Clin Pract* 2005; 59(10): 1187-1194. [PubMed] [Full Text]
39. **Halpin DMG**. Beta2 agonist reversibility testing in COPD diagnosis. *Drug Ther Bull* 2005; 43(12): 89-91. [PubMed] [Full Text]
40. **Halpin DMG**. The diagnosis and management of COPD in older people. *CME Geriatric Medicine* 2006; 8:11-17.
41. **Halpin DMG**. Health economics of chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2006; 3(3):227-233. [PubMed] [Full Text]

42. **Halpin DMG.** Assessing the severity of COPD. *Prim Care Respir J* 2006; 15(2): 78-80. [PubMed] [Full Text]
43. **Halpin DMG.** Chronic obstructive pulmonary disease, inflammation and PDE4 inhibitors. *Br J Hosp Med (Lond)* 2006; 67(7): 370-374. [PubMed] [Full Text]
44. **Halpin DMG.** Diagnosing COPD. *Int J Chron Obstruct Pulmon Dis* 2006; 1(4): 343-344. [PubMed] [Full Text]
45. Dyer MJ, **Halpin DM,** et al. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. *BMC Fam Pract* 2006; 7: 34. [PubMed] [Full Text]
46. **Halpin DMG,** et al. Chronic obstructive pulmonary disease: the disease and its burden to society. *Proc Am Thorac Soc* 2006; 3(7): 619-623. [PubMed] [Full Text]
47. **Halpin DMG.** Systemic effects of chronic obstructive pulmonary disease. *Expert Rev Resp Med* 2007; 1(1): 75-84. [PubMed] [Full Text]
48. **Halpin DMG.** Management of exacerbations of chronic obstructive pulmonary disease. *Minerva Pulmonol* 2007; 46(1):5-17. [Full Text]
49. **Halpin DM,** et al. BTS COPD Consortium. Confidence and understanding among general practitioners and practice nurses in the UK about diagnosis and management of COPD. *Respir Med* 2007; 101(11): 2378-2385. [PubMed] [Full Text]
50. Seamark DA, **Halpin DM,** et al. Palliative care in chronic obstructive pulmonary disease: a review for clinicians. *J R Soc Med* 2007; 100(5): 225-233. [PubMed] [Full Text]
51. **Halpin DM.** Community care for COPD: the good, the bad and the ugly. *Thorax* 2008; 63(3):187-189. [PubMed] [Full Text]
52. **Halpin D.** Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. *COPD* 2008; 5(3):187-200. [PubMed] [Full Text]
53. **Halpin DM,** et al. End-of-life care for patients with COPD in the community setting. *Br J Gen Pract* 2008; 58(551): 390-392. [PubMed] [Full Text]
54. Crowe E, **Halpin D,** et al. Early identification and management of chronic kidney disease: summary of NICE guidance. *BMJ* 2008; 337: 812-815. [PubMed] [Full Text]
55. **Halpin DM,** et al. Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. *Respir Med* 2008; 102(11):1615-1624. [PubMed] [Full Text]
56. **Halpin DMG.** Symbicort: a pharmaco-economic review. *J Med Econ* 2008; 11(2):345-362. [PubMed] [Full Text]
57. **Halpin DMG.** Uplifting times for COPD. *Prim Care Respir J* 2008; 17(4): 197-198. [PubMed] [Full Text]
58. **Halpin DMG.** ABCD of the phosphodiesterase family: interaction and differential activity in COPD. *Int J Chron Obstruct Pulmon Dis* 2008; 3(4): 543-561. [PubMed] [Full Text]
59. Hyland ME, **Halpin DM,** et al. Guidelines versus practice: UK asthma nurses often recommend intermittent, symptom-driven use of inhaled corticosteroids. *Prim Care Respir J* 2009; 18(2): 114-117. [PubMed] [Full Text]
60. **Halpin D,** et al. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. *Prim Care Respir J* 2009; 18(2): 106-113. [PubMed] [Full Text]
61. Bryden C, **Halpin DM,** et al. Stratification of COPD patients by previous admission for targeting of preventative care. *Respir Med* 2009; 103(4): 558-565. [PubMed] [Full Text]
62. **Halpin DMG,** et al. Palliative and end-of-life care for patients with respiratory disease. *Eur Respir Monograph* 2009; 43: 327-353. [Full Text]
63. **Halpin DM,** et al. Defining disease modification in chronic obstructive pulmonary disease. *COPD* 2009; 6(3): 211-225. [PubMed] [Full Text]
64. Gott M, **Halpin D,** et al. Barriers to advance care planning in chronic obstructive pulmonary disease. *Palliat Med* 2009; 23(7): 642-648. [PubMed] [Full Text]
65. **Halpin DM.** Preventing chronic obstructive pulmonary disease. *Expert Rev Resp Med* 2009; 3(5): 449-452. [PubMed] [Full Text]
66. Gardiner C, **Halpin D,** et al. Living with advanced chronic obstructive pulmonary disease: patients concerns regarding death and dying. *Palliat Med* 2009; 23(8): 691-697. [PubMed] [Full Text]
67. **Halpin DM.** Lessons from the major studies in COPD: problems and pitfalls in translating research evidence into practice. *Prim Care Respir J* 2010; 19(2): 170-179. [PubMed] [Full Text]
68. Gardiner C, **Halpin D,** et al. Exploring the care needs of patients with advanced COPD: an overview of the literature. *Respir Med* 2010; 104(2): 159-165. [PubMed] [Full Text]
69. Marno P, **Halpin D,** et al. Can a health forecasting service offer COPD patients a novel way to manage their condition? *J Health Serv Res Policy* 2010; 15(3): 150-155. [PubMed] [Full Text]
70. Gardiner C, **Halpin D,** et al. Reconciling informed consent and 'do no harm': ethical challenges in palliative-care research and practice in chronic obstructive pulmonary disease. *Palliat Med* 2010; 24(5): 469-472. [PubMed] [Full Text]
71. **Halpin DMG.** Investigation and treatment of severe chronic obstructive pulmonary disease. *Respiratory Disease in Practice* 2010;21:7-8.
72. Small N, **Halpin D,** et al. Using a prediction of death in the next 12 months as a prompt for referral to palliative care acts to the detriment of patients with heart failure and chronic obstructive pulmonary disease. *Palliat Med* 2010; 24(7): 740-741. [PubMed] [Full Text]
73. **Halpin DM.** Improving the management of COPD. *BMJ* 2011; 342: d1674. [PubMed] [Full Text]

74. **Halpin DM**, et al. A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. *Prim Care Respir J* 2011; 20(3): 324-331. [PubMed] [Full Text]
75. **Halpin DM**, et al. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. *Int J Clin Pract* 2011; 65(7): 764-774. [PubMed] [Full Text]
76. **Halpin DM**, et al. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT trial. *Lung* 2011; 189(4): 261-268. [PubMed] [Full Text]
77. Small N, **Halpin D**, et al. "You get old, you get breathless, and you die": Chronic obstructive pulmonary disease in Barnsley, UK. *Health Place* 2012; 18(6): 1396-1403. [PubMed] [Full Text]
78. Hyland ME, **Halpin DM**, et al. Frequency of non-asthma GP visits predicts asthma exacerbations: an observational study in general practice. *Prim Care Respir J* 2012; 21(4): 405-411. [PubMed] [Full Text]
79. Barnes S, **Halpin D**, et al. Enhancing Patient-Professional Communication About End-of-Life Issues in Life-Limiting Conditions: A Critical Review of the Literature. *J Pain Symptom Manage* 2012; 44(6): 866-879. [PubMed] [Full Text]
80. Seamark D, **Halpin D**, et al. Is hospitalisation for COPD an opportunity for advance care planning? A qualitative study. *Prim Care Respir J* 2012; 21(3) :261-266. [PubMed] [Full Text]
81. Tashkin DP, **Halpin D**, et al. Comparison of the variability of the annual rates of change in FEV1 determined from serial measurements of the pre- versus post-bronchodilator FEV1 over 5 years in mild to moderate COPD: results of the lung health study. *Respir Res* 2012; 13: 70. [PubMed] [Full Text]
82. **Halpin DM**, et al. Exacerbation frequency and course of COPD. *Int J Chron Obstruct Pulmon Dis* 2012; 7: 653-661. [PubMed] [Full Text]
83. Tashkin DP, **Halpin D**, et al. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. *Respir Med* 2013; 107(12): 1904-1911. [PubMed] [Full Text]
84. Jones RCM, **Halpin DMG**, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. *Lancet Respir Med* 2014; 2(4): 267-276. [PubMed] [Full Text]
85. Tashkin DP, **Halpin D**, et al. Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. *Respir Res* 2014; 15: 102. [PubMed] [Full Text]
86. **Halpin DM**, et al. The WISDOM of inhaled corticosteroids in COPD. *Thorax* 2014; 69(12): 1071-1072. [PubMed] [Full Text]
87. Sarran C, **Halpin D**, et al. A retrospective study of the impact of a telephone alert service (Healthy Outlook) on hospital admissions for patients with chronic obstructive pulmonary disease. *NPJ Prim Care Respir Med* 2014; 24:14080. [PubMed] [Full Text]
88. Chamberlain C, **Halpin DM**, et al. Investigating Women's Experiences of Asthma Care in Pregnancy: A Qualitative Study. *Open Nurs J* 2014; 8: 56-63. [PubMed] [Full Text]
89. **Halpin D**, et al. Improving inhaler technique. *Practice Nursing* 2015; 26: 16-20. [Full Text]
90. **Halpin DMG**, et al. Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFT® Randomized Controlled Trial. *Chronic Obstr Pulm Dis (Miami)* 2015; 2(3): 236-251. [PubMed] [Full Text]
91. **Halpin D**, et al. South West Respiratory Network inhaler training project. *Nurse Prescribing* 2015;13:130-135.[Full Text]
92. **Halpin D**, et al. Understanding fear and anxiety in patients at the time of an exacerbation of chronic obstructive pulmonary disease: a qualitative study. *JRSM Open* 2015; 6(12): 2054270415614543. [PubMed] [Full Text]
93. Saleh A.; European COPD Audit team (**Halpin D**). The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data from the European COPD Audit. *PLoS One* 2015; 10(7): e0134004. [PubMed] [Full Text]
94. **Halpin DM**, et al. Tiotropium HandiHaler® and Respimat® in COPD: a pooled safety analysis. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 239-59. [PubMed] [Full Text]
95. Paggiaro P, **Halpin DM**, et al. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. *J Allergy Clin Immunol Pract* 2016; 4(1): 104-113.e2. [PubMed] [Full Text]
96. Miravittles M, **Halpin D**, et al. A review of national guidelines for management of COPD in Europe. *Eur Respir J* 2016; 47(2): 625-637. [PubMed] [Full Text]
97. **Halpin D**, et al. Working together to go 'beyond the pill': building a virtuous network of collaborators. *BMJ Innov* 2016; 2: 1-3. [Full Text]
98. Lange P, **Halpin DM**, et al. Diagnosis, assessment, and phenotyping of COPD: beyond FEV<sub>1</sub>. *Int J Chron Obstruct Pulmon Dis* 2016; 11 Spec Iss: 3-12. [PubMed] [Full Text]
99. **Halpin D**, et al. Case finding for chronic obstructive pulmonary disease in people attending long-term condition clinics in primary care. *Chron Respir Dis* 2016; 13: 337-343. [PubMed] [Full Text]
100. **Halpin DM**, et al. Effect of tiotropium on COPD exacerbations: A systematic review. *Respir Med* 2016; 114: 1-8. [PubMed] [Full Text]
101. Dahl R, **Halpin D**, et al. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. *Respir Med* 2016; 118: 102-11. [PubMed] [Full Text]

102. Hyland ME, **Halpin DM**, et al. Preference for different relaxation techniques by COPD patients: comparison between six techniques. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 2315-2319. [PubMed] [Full Text]
103. **Halpin DM**. Tiotropium in asthma: what is the evidence and how does it fit in? *World Allergy Organ J* 2016; 9(1): 29. [PubMed] [Full Text]
104. **Halpin DM**, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. *Respir Res* 2016; 17(1): 120. [PubMed] [Full Text]
105. Singh D, **Halpin D**, et al. Current Controversies in the Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2016; 194(5): 541-549. [PubMed] [Full Text]
106. Vogelmeier CF, **Halpin DM**, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Am J Respir Crit Care Med* 2017; 195(5): 557-582. [PubMed] [Full Text]
107. Vogelmeier CF, **Halpin DM**, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Eur Respir J* 2017; 49(3) pii: 1700214. [PubMed] [Full Text]
108. Vogelmeier CF, **Halpin DM**, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Respirology* 2017; 22(3): 575-601. [PubMed] [Full Text]
109. Vogelmeier CF, **Halpin DM**, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. *Arch Bronconeumol* 2017; 53(3): 128-149. [PubMed] [Full Text]
110. **Halpin DM**, et al. Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. *Respir Med* 2017; 128: 28-41. [PubMed] [Full Text]
111. **Halpin DMG**, et al. Effect of a single exacerbation on decline in lung function in COPD. *Respir Med* 2017; 128: 85-91. [PubMed] [Full Text]
112. **Halpin DM**, et al. Impact and prevention of severe exacerbations of COPD: a review of the evidence. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2891-2908. [PubMed] [Full Text]
113. Thomas M, **Halpin DM**, et al. When is dual bronchodilation indicated in COPD? *Int J Chron Obstruct Pulmon Dis*. 2017; 12: 2291-2305. [PubMed] [Full Text]
114. Miravittles M, **Halpin D**, et al. Chronic obstructive pulmonary disease guidelines in Europe: a look into the future. *Respir Res* 2018; 19(1): 11. [PubMed] [Full Text]
115. **Halpin DMG**. The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease. *Tuberc Respir Dis (Seoul)* 2018; 81(1): 13-18. [PubMed] [Full Text]
116. **Halpin DMG**. Palliative care for people with COPD: effective but underused. *Eur Respir J* 2018; 51(2):pii: 1702645. [PubMed] [Full Text]